Published in World J Hepatol on October 18, 2015
Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys. Adv Nutr (2016) 0.76
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases. Diagnostics (Basel) (2016) 0.75
Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion. World J Gastroenterol (2017) 0.75
Iridoids are natural glycation inhibitors. Glycoconj J (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med (1988) 7.22
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 5.49
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (2010) 5.44
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Advanced protein glycosylation in diabetes and aging. Annu Rev Med (1995) 4.13
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology (1999) 3.99
Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest (1994) 3.70
Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev (2010) 3.60
Diabetes and advanced glycation endproducts. J Intern Med (2002) 3.38
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science (1981) 3.25
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J (1999) 2.61
The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem (1996) 2.42
Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol (1996) 2.39
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut (2004) 2.15
Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med (2007) 2.14
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des (2005) 2.06
Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol (1992) 2.04
Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab (2010) 1.97
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology (2000) 1.96
Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol (2014) 1.94
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer (2011) 1.89
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol (2002) 1.82
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol (2002) 1.76
Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem (1995) 1.76
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 1.60
Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol (2008) 1.49
Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem (2006) 1.44
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Dietary fructose in nonalcoholic fatty liver disease. Hepatology (2013) 1.39
RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med (2005) 1.35
Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys (2003) 1.30
Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep (2002) 1.30
Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology (2001) 1.29
Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol (2010) 1.28
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism (2006) 1.26
AGE-RAGE system and carcinogenesis. Curr Pharm Des (2008) 1.24
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta (2011) 1.23
Management of hepatocellular carcinoma. Rev Gastroenterol Disord (2003) 1.21
Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res (2003) 1.18
Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol (2014) 1.17
Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res (2011) 1.14
TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med (2006) 1.10
Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des (2008) 1.10
Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol (2004) 1.09
Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des (2008) 1.07
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol (2011) 1.06
Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep (2000) 1.05
Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl (2001) 1.05
Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis (2009) 1.01
Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med (1999) 1.01
The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem (2014) 1.00
A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol (2007) 0.99
Reactive metabolites and AGE-RAGE-mediated inflammation in patients following liver transplantation. Mediators Inflamm (2013) 0.99
Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr Mol Med (2001) 0.99
Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int (2014) 0.98
Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res (2006) 0.98
Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol (2014) 0.98
Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol (2006) 0.96
Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol (2010) 0.96
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med (2008) 0.95
TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses (2004) 0.94
Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg (2012) 0.94
Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncol Rep (2010) 0.93
Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem (2006) 0.93
Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol (2008) 0.92
Immunological detection of a novel advanced glycation end-product. Mol Med (2001) 0.92
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia (2006) 0.92
Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology (2006) 0.92
Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol (2011) 0.92
Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology (2005) 0.91
Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal (2013) 0.91
Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology (2013) 0.90
Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Curr Drug Targets (2010) 0.90
C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol (2013) 0.90
Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients (2013) 0.89
Advanced glycation end products: detection and reversal. Methods Enzymol (1999) 0.89
Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol (2013) 0.89
MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. World J Gastroenterol (2010) 0.87
Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol (2012) 0.86
Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation. Br J Pharmacol (2013) 0.86
Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem (2009) 0.85
Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling. Mol Carcinog (2014) 0.83
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol (2007) 0.83
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett (2006) 0.83
Hepatic stellate cells secretes type I collagen to trigger epithelial mesenchymal transition of hepatoma cells. Am J Cancer Res (2014) 0.82
In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM. World J Gastroenterol (2015) 0.76